Alteration of Cyclosporin-A Pharmacokinetics after Experimental Spinal Cord Injury

Authors:
  • DCDolores Correa
    Dolores Correa
  • RKRoberto Kretschmer
    Roberto Kretschmer
  • IGIsrael Grijalva
    Israel Grijalva
  • FFFrancisco J. Flores-Murrieta
    Francisco J. Flores-Murrieta
  • GCGilberto Castañeda-Hernández
    Gilberto Castañeda-Hernández
  • AOAlberto Odor
    Alberto Odor
  • RLRosa M. López
    Rosa M. López
  • RFRebecca Franco-Bourland
    Rebecca Franco-Bourland
  • AEAna L. Espitia
    Ana L. Espitia
  • HSHermelinda Salgado-Ceballos
    Hermelinda Salgado-Ceballos

Abstract
The pharmacokinetics of the immunosuppressive agent cyclosporin-A (CsA) were studied in rats submitted to spinal cord (SC) injury. A single CsA 10 mg/kg dose was given either intraperitoneally (i.p.) or orally to rats submitted to experimental SC injury at the T8 level. Twenty four hours after lesion (acute stage of SC injury) i.p. CsA bioavailability was increased, while t1/2 was prolonged. However, oral bioavailability was reduced. Seven weeks after lesion (chronic stage of SC injury) CsA bioavailability, by either route, was not significantly different from control values. Results indicate that parenteral CsA bioavailability is increased during the acute stage of SC lesion, probably due to an impaired elimination. Oral bioavailability, however, is decreased, since there is also an important reduction in gastrointestinal CsA absorption that overrides the effect of impaired elimination. Alterations in CsA pharmacokinetics appear to revert during the chronic stage of SC injury. Changes in CsA bioavailability, depending on the route of administration and on time, must be considered to design an adequate immunosuppressive treatment in SC injury.

This publication has 12 references indexed in Scilit: